Surgical Treatment of Recurrent Lung Cancer

재발성 비소세포암의 수술적 치료

  • 유원희 (서울대학교 병원 흉부외과 서울대학교 의과대학 흉부외과학교실) ;
  • 김문수 (서울대학교 병원 흉부외과 서울대학교 의과대학 흉부외과학교실) ;
  • 김영태 (서울대학교 병원 흉부외과 서울대학교 의과대학 흉부외과학교) ;
  • 성숙환 (서울대학교 병원 흉부외과 서울대학교 의과대학 흉부외과학교실) ;
  • 김주현 (서울대학교 병원 흉부외과 서울대학교 의과대학 흉부외과학교실)
  • Published : 2000.01.01

Abstract

Background: The resection of recurrent non-small cell lung cancer can be performed very rarely. There has been many arguments for longterm result and therapeutic role in surgical management of recurrent non-small cell lung cancer(NSCLC). We analyze our result of surgical re-resection of recurrent NSCLC for 10 years retrospectively. Material and Method: In the period from 1987 to 1997, 702 patients who had been confirmed for NSCLC had undergone complete resection in Seoul National University Hospital. As December 1997, 22 of these patients have been operated on the diagnosis of recurrent lung cancer. In these patients one has revealed for benign nodule at postoperative pathologic pathologic was unresectable. and two had revealed other cell type on postoperative pathologic examination. Analysis about postoperative survival rate and the factors that influence postoperative survival rate - sex, age, pathologic stage, cell type, operation adjuvant therapy after first and second operation location of recurrence disease free survival-was 59.1$\pm$10.9 year. There were 14 men and 3 women. Four patients was received radiation therpy after first opration and two patients was received postoperative chemotherapy. At first operation 2 patients was stage Ia, 8 was stage Ib, 1 was stage IIa 6 was stage IIb. Eleven patients had squamous. cell carcinoma at postoperatrive pathologic examination five had adenocarcinoma and one had bronchioalveolar carcinoma. In second operation 8 patients were received limited resection. 9 were received lobectomy or pneumonectomy. One-year survival rate was 82.4% and five-year survival rate was 58.2% Non-adjuvant therapy group after initial operation was more survived than adjuvant therapy group statistically. Conclusion: operation was more survived than adjuvant therapy group statistically. Conclusion : Operation was feasible treatment modality for re-resectable non-small cell lung cancer. But we cannot rule out possibility of double primary lung cancer for them. Postoperative prognostic factor was adjuvant therapy or nor after first oepration but further study of large scale is needed for stastically more valuable result.

Keywords

References

  1. Chest v.89 no.Sup. A new international staging system for lung cancer Mountain CF.
  2. J R Stat Soc (B) v.34 Regression models and life-tables Cox DR.
  3. J Thorac Cardiovasc surg v.99 no.5 Multiple primary lung cancers. Results of surgical treatment Deschamps C;Pairolero PC;Trastek VF;Payne WS.
  4. Chung Hua Chung Liu Tsa Chih v.17 no.1 The result of re-resection of lung cancer Gao W;Din J;Jin F.
  5. Surgery of the Chest. (6th edition) Neoplasm of the Lung Thomas A;D'Amico;Daved C;Sabiston F;Sabiston Dc Jr;Spencer F.
  6. J Thorac Cardiovasc Surg v.94 Postoperative TINO non-small cell lung cancer Thomas PA;Piantadosi S.
  7. J Thorac Cardiovasc Surg v.108 Postrecurrent survival of patients with non-small-cell lung cancer undergoing a complete resection Ichinose Y;Yano T;Yokoyama H;Inoue T;Asoh H.
  8. Cancer Chemother Rep v.4 Effects of long term adjuvant chemoterapy with cyclophosphamide (NSC-26271) for radically resected bronchogenic carcinoma Brunner KW;Marthaler T;Muller W.
  9. Cancer v.50 Prolonged intermittent adjuvant chemotherapy with CCNU and hydrozyurea after resection of carcinoma of the lung Shields TW;Higgins GA;Humphrey EW;Matthews MJ:Keehn RJ.
  10. J Surg Oncol v.46 Postoperative adjuvant chemotherapy in non-small cell lung cancer: prognostic value of DNA diploidy and postrecurrent survival Ichinose Y;hara N;Ohta M;Motohiro A;Kudo T;Asoh H.